comment until March 25, 2011. This process is conducted in accordance with 5 CFR 1320.10. To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: DOJ Desk Officer, Fax: 202–395–7285, or be e-mailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number [1140–0078]. Also, include the DOJ docket number found in brackets in the heading of this document. If you have questions concerning the collection, please contact William Miller, William.Miller@atf.gov or the DOJ Desk Officer at 202–395–3176.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Enhance the quality, utility, and clarity of the information to be collected; and

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of This Information Collection

(1) Type of Information Collection: Extension of a currently approved collection.

(2) Title of the Form/Collection: Limited Permittee Transaction Record.

(3) Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form Number: None. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Business or other for-profit. Other: Individuals or households. Abstract: The purpose of this collection is to ensure that records are available for tracing explosive materials when necessary and to ensure that limited permittees do not exceed their maximum allotment of receipts of explosive materials.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: There will be an estimated 5,000 respondents, who will spend approximately 5 minutes to receive, file, and forward the appropriate documentation.

(6) An estimate of the total burden (in hours) associated with the collection: There are an estimated 12,000 total burden hours associated with this collection.

If additional information is required contact: Lynn Murray, Department Clearance Officer, United States Department of Justice, Policy and Planning Staff, Justice Management Division, Two Constitution Square, Room 2E–502, 145 N Street, NE., Washington, DC 20530.

Dated: February 16, 2011.

Lynn Murray,
Department Clearance Officer, PRA, United States Department of Justice.

BILLING CODE 4410–FY–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on January 4, 2011, Sigma Aldrich Manufacturing LLC., 3500 Dekalb Street, St. Louis, Missouri 63118, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cathinone (1235)</td>
<td>I</td>
</tr>
<tr>
<td>Methcathinone (1237)</td>
<td>I</td>
</tr>
<tr>
<td>Aminorex (1585)</td>
<td>I</td>
</tr>
<tr>
<td>Gamma Hydroxybutyric Acid (2010)</td>
<td>I</td>
</tr>
<tr>
<td>Methaqualone (2565)</td>
<td>I</td>
</tr>
<tr>
<td>Alpha-ethyltryptamine (7249)</td>
<td>I</td>
</tr>
<tr>
<td>Ibogaine (7280)</td>
<td>I</td>
</tr>
<tr>
<td>Lysergic acid diethylamide (7315)</td>
<td>I</td>
</tr>
<tr>
<td>Marihuana (7360)</td>
<td>I</td>
</tr>
<tr>
<td>Tetrahydrocannabinols (7370)</td>
<td>I</td>
</tr>
<tr>
<td>Mescaline (7381)</td>
<td>I</td>
</tr>
<tr>
<td>4-Bromo-2,5-dimethoxyamphetamine (7391)</td>
<td>I</td>
</tr>
<tr>
<td>4-Bromo-2,5-dimethoxyphenethylamine (7392)</td>
<td>I</td>
</tr>
<tr>
<td>4-Methyl-2,5-dimethoxyamphetamine (7395)</td>
<td>I</td>
</tr>
<tr>
<td>2,5-Dimethoxyamphetamine (7396)</td>
<td>I</td>
</tr>
<tr>
<td>3,4-Methylenedioxyamphetamine (7400)</td>
<td>I</td>
</tr>
<tr>
<td>N-Hydroxy-3,4-methylenedioxymethylamphetamine (MDMA) (7405)</td>
<td>I</td>
</tr>
<tr>
<td>3,4-Methylenedioxy-N-ethylamphetamine (7404)</td>
<td>I</td>
</tr>
<tr>
<td>3,4-Methylenedioxyethylamphetamine (7402)</td>
<td>I</td>
</tr>
<tr>
<td>Bufotenine (7433)</td>
<td>I</td>
</tr>
</tbody>
</table>
### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

#### Imposter of Controlled Substances; Notice of Application

By Notice dated November 1, 2010, and published in the Federal Register on November 12, 2010, 75 FR 69461, Wildlife Laboratories, 1401 Duff Drive, Suite 400, Fort Collins, Colorado 80524, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Etorphine Hydrochloride (9059), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 6, 2011, Johnson Matthey Pharmaceutical Materials Inc., Pharmaceutical Service, 25 Patton Road, Devens, Massachusetts 01434, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine (1100)</td>
<td>II</td>
</tr>
<tr>
<td>Methylphenidate (1724)</td>
<td>II</td>
</tr>
<tr>
<td>Nabilone (7379)</td>
<td>II</td>
</tr>
<tr>
<td>Sufentanil (9740)</td>
<td>II</td>
</tr>
<tr>
<td>Hydrocodone (9193)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company’s primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company’s customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a) and determined that the registration of Wildlife Laboratories to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Wildlife Laboratories to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history.

Therefore, pursuant to 21 U.S.C. 958(a) and 958(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as an importer of the basic class of controlled substance listed.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

BILLY CODE 4410–09–P

### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 6, 2011, Johnson Matthey Pharmaceutical Materials Inc., Pharmaceutical Service, 25 Patton Road, Devens, Massachusetts 01434, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine (9300)</td>
<td>II</td>
</tr>
<tr>
<td>Thebaine (9333)</td>
<td>II</td>
</tr>
<tr>
<td>Opium, powdered (9639)</td>
<td>II</td>
</tr>
<tr>
<td>Levo-alphacetylmethadol (9648)</td>
<td>II</td>
</tr>
<tr>
<td>Oxymorphone (9652)</td>
<td>II</td>
</tr>
<tr>
<td>Fentanyl (9801)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company’s primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company’s customers.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 25, 2011.


Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

BILLY CODE 4410–09–P

### Drug Schedule

- **Schedule I**
  - Codeine (9050)
  - Etorphine Hydrochloride (9059)
  - Fentanyl (9801)
  - Methadone (9200)
  - Methamphetamine (1100)
  - Methylenediphenyl (9170)
  - N-Benzylpiperazine (BZP) (7493)
  - Phencyclidine (7471)
  - Secobarbital (2315)
  - Secobarbital (2315)
  - Serotonin (1724)
  - N-Benzylpiperazine (BZP) (7493)
  - Phencyclidine (7471)
  - Secobarbital (2315)
  - Secobarbital (2315)
  - Serotonin (1724)

- **Schedule II**
  - Codeine (9050)
  - Etorphine Hydrochloride (9059)
  - Fentanyl (9801)
  - Methadone (9200)
  - Methamphetamine (1100)
  - Methylenediphenyl (9170)
  - N-Benzylpiperazine (BZP) (7493)
  - Phencyclidine (7471)
  - Secobarbital (2315)
  - Secobarbital (2315)
  - Serotonin (1724)

- **Schedule III**
  - Codeine (9050)
  - Etorphine Hydrochloride (9059)
  - Fentanyl (9801)
  - Methadone (9200)
  - Methamphetamine (1100)
  - Methylenediphenyl (9170)
  - N-Benzylpiperazine (BZP) (7493)
  - Phencyclidine (7471)
  - Secobarbital (2315)
  - Secobarbital (2315)
  - Serotonin (1724)

- **Schedule IV**
  - Codeine (9050)
  - Etorphine Hydrochloride (9059)
  - Fentanyl (9801)
  - Methadone (9200)
  - Methamphetamine (1100)
  - Methylenediphenyl (9170)
  - N-Benzylpiperazine (BZP) (7493)
  - Phencyclidine (7471)
  - Secobarbital (2315)
  - Secobarbital (2315)
  - Serotonin (1724)

- **Schedule V**
  - Codeine (9050)
  - Etorphine Hydrochloride (9059)
  - Fentanyl (9801)
  - Methadone (9200)
  - Methamphetamine (1100)
  - Methylenediphenyl (9170)
  - N-Benzylpiperazine (BZP) (7493)
  - Phencyclidine (7471)
  - Secobarbital (2315)
  - Secobarbital (2315)
  - Serotonin (1724)